PCV chemotherapy for recurrent glioblastoma

Neurology. 2006 Feb 28;66(4):587-9. doi: 10.1212/01.wnl.0000197792.73656.c2.

Abstract

The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Glioblastoma / drug therapy*
  • Humans
  • Lomustine / administration & dosage
  • Male
  • Middle Aged
  • Procarbazine / administration & dosage
  • Recurrence
  • Time Factors
  • Vincristine / administration & dosage

Substances

  • Procarbazine
  • Vincristine
  • Lomustine

Supplementary concepts

  • PCV protocol